litlas
Log inCreate account

Vivek Subbiah

Active 2009–2025

250
Papers
24,864
Citations
79
h-index
232
i10-index

Citations

Citations per year for Vivek Subbiah1996: 2 citations1997: 2 citations2000: 1 citations2003: 1 citations2004: 1 citations2006: 1 citations2009: 4 citations2010: 6 citations2011: 4 citations2012: 5 citations2013: 2 citations2015: 7 citations2016: 66 citations2017: 151 citations2018: 153 citations2019: 600 citations2020: 1,106 citations2021: 1,302 citations2022: 1,394 citations2023: 1,468 citations2024: 2,346 citations2025: 1,317 citations2026: 24 citations1998–1999: no citations, so these years are not shown2001–2002: no citations, so these years are not shown2005: no citations, so this year is not shown2007–2008: no citations, so these years are not shown2014: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,973 citing papers, 26.3% of this breakdownChina: 1,285 citing papers, 11.3% of this breakdownItaly: 773 citing papers, 6.8% of this breakdownUnited Kingdom: 562 citing papers, 5% of this breakdownFrance: 538 citing papers, 4.7% of this breakdownGermany: 531 citing papers, 4.7% of this breakdownSpain: 454 citing papers, 4% of this breakdownJapan: 348 citing papers, 3.1% of this breakdownCanada: 336 citing papers, 3% of this breakdownNetherlands: 292 citing papers, 2.6% of this breakdownSwitzerland: 289 citing papers, 2.5% of this breakdownAustralia: 275 citing papers, 2.4% of this breakdown
0%26.3%Other 23.6%

Institutions

Fields

  • Medicine66.3%
  • Biochemistry, Genetics and Molecular Biology26.6%
  • Immunology and Microbiology1.9%
  • Computer Science1%
  • Mathematics0.7%
  • Engineering0.6%
  • Other2.9%

Topics

  • Cancer Genomics and Diagnostics6.2%
  • Lung Cancer Treatments and Mutations5.9%
  • Cancer Immunotherapy and Biomarkers5.3%
  • Lung Cancer Research Studies3%
  • Thyroid Cancer Diagnosis and Treatment2.6%
  • Colorectal Cancer Treatments and Studies2.1%
  • Other74.9%

Coauthors

All papers

Open in search
  1. The next generation of evidence-based medicine

    Authors: Vivek Subbiah - Nature Medicine 2023 cited by 528

  2. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

    Authors: Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam, Hagop M. Kantarjian, Farhad Ravandi, Meghan Collins, Maria Emilia Di Francesco, Ecaterina E. Dumbrava, Siqing Fu, Sisi Gao, Jason Gay, Sonal Gera, Jing Han, David S. Hong, Elias Jabbour, Zhenlin Ju, Daniel D. Karp, Alessia Lodi, Jennifer R. Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A. Piha‐Paul, Jordi Rodón, Carolina Salguero, Koji Sasaki, Anand Kumar Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun A. Xu, Musa Yılmaz, Qi Zhang, Yuan Li, Christopher A. Bristow, Meenakshi B. Bhattacharjee, Stefano Tiziani, Timothy P. Heffernan, Christopher P. Vellano, Philip Jones, Cobi J. Heijnen, Annemieke Kavelaars, Joseph R. Marszalek, Marina Konopleva - Nature Medicine 2023 cited by 377

  3. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

    Authors: Vivek Subbiah, Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss, Masayuki Takeda, Yuichiro Ohe, Saad A. Khan, Kadoaki Ohashi, Victoria Soldatenkova, Sylwia Szymczak, Loretta Sullivan, Jennifer Wright, Alexander Drilon - The Lancet Oncology 2022 cited by 420

  4. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 cited by 836

  5. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Authors: David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean‐Yves Blay, Jürgen Wolf, Noopur Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoîne Italiano, Ralf‐Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schüler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzén, Maria Luisa Veronese, Josep Tabernero, José Baselga - New England Journal of Medicine 2015 cited by 1,734

  6. Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

    Authors: Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas - New England Journal of Medicine 2020 cited by 773

  7. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

    Authors: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J.A. de Jonge, Jean‐Yves Blay, Antoîne Italiano, Kan Yonemori, Daniel C. Cho, Filip De Vos, Philippe Moreau, Elena Élez, Jan H.M. Schellens, Christoph Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung‐Jue Bang - Nature Medicine 2023 cited by 298

  8. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    Authors: Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan, Elena Garralda, Luis Paz‐Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen V. Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah - The Lancet Oncology 2021 cited by 443

  9. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    Authors: Giannis Mountzios, Jordi Remón, Lizza Hendriks, Rosario García‐Campelo, Christian Rolfo, Paul Van Schil, Patrick M. Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean‐Charles Soria, Solange Peters - Nature Reviews Clinical Oncology 2023 cited by 182

  10. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Authors: Vivek Subbiah, Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg - The Lancet Oncology 2020 cited by 518

  11. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    Authors: José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares - The Lancet Oncology 2020 cited by 462

  12. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

    Authors: Patrick Y Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos, Nikolas von Bubnoff, Myra E van Linde, Albert Lai, Gerald W Prager, Mario Campone, Angelica Fasolo, Jose A Lopez-Martin, Tae Min Kim, Warren P Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah - The Lancet Oncology 2021 cited by 353

  13. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

    Authors: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean Charles Soria, Patrick Y. Wen, Christoph Zielinski, Maria E. Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, Fatima Rangwala, Bhumsuk Keam - Journal of Clinical Oncology 2017 cited by 885

  14. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

    Authors: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria, Patrick Y. Wen, C. C. Zielinski, Maria E. Cabanillas, Aislyn Boran, Palanichamy Ilankumaran, P. Burgess, T. Romero Salas, Bhumsuk Keam - Annals of Oncology 2022 cited by 346

  15. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

    Authors: Matteo Palmeri, Janice M. Mehnert, Ann W. Silk, Salma K. Jabbour, Shridar Ganesan, Pallvi Popli, Gregory Riedlinger, Ryan D. Stephenson, Alexandre Buckley de Meritens, Aliza Leiser, Tina Mayer, Nancy Chan, Kristen Spencer, Eugenia Girda, Jyoti Malhotra, Timothy A. Chan, Vivek Subbiah, Roman Groisberg - ESMO Open 2021 cited by 353

  16. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Authors: Vivek Subbiah, Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P. Kalemkerian, Daniel W. Bowles, ­Mahesh Seetharam, Jianhua Chang, Hui Zhang, Jennifer Green, Alena Zalutskaya, Martin Schüler, Yun Fan, Giuseppe Curigliano - Nature Medicine 2022 cited by 239

  17. Clinical Development of BRAF plus MEK Inhibitor Combinations

    Authors: Vivek Subbiah, Christina S. Baik, John M. Kirkwood - Trends in cancer 2020 cited by 352

  18. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

    Authors: Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin Solomon, Daniel S.W. Tan, Guzmán Alonso, Jürgen Wolf, Keunchil Park, Kōichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott Barker, Tarun Puri, Aimee Bence Lin, Herbert H. Loong, Benjamin Besse - Journal of Clinical Oncology 2022 cited by 205

  19. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

    Authors: Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry Touré, Songping Zhao, Roberto Valverde, Patrick J. O’Hearn, Demetri T. Moustakas, Heike Schönherr, Nastaran Gerami-Moayed, Alexander M. Taylor, Brandi M. Hudson, Damian J. Houde, Debjani Pal, Lindsey Foster, Hakan Günaydin, Pelin Ayaz, Dina A. Sharon, Lipika Goyal, Alison M. Schram, Suneel Kamath, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Kai Yu Jen, Fabien Ricard, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, Jessica B. Casaletto - Cancer Discovery 2023 cited by 119

  20. Drugging KRAS: current perspectives and state-of-art review

    Authors: Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah, Alfredo Addeo - Journal of Hematology & Oncology 2022 cited by 146

  21. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    Authors: Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano, Marcia S. Brose, Viola W. Zhu, Sophie Leboulleux, Daniel W. Bowles, Christina S. Baik, Douglas Adkins, Bhumsuk Keam, Ignacio Matos, Elena Garralda, Justin F. Gainor, Gilberto Lopes, Chia‐Chi Lin, Yann Godbert, Debashis Sarker, Stephen G. Miller, Corinne Clifford, Hui Zhang, Christopher D. Turner, Matthew H. Taylor - The Lancet Diabetes & Endocrinology 2021 cited by 353

  22. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

    Authors: Frank Griesinger, Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan, Daniel Lee, D Misch, Elena Garralda, D.-W. Kim, Anthonie J. van der Wekken, Justin F. Gainor, Luis Paz‐Ares, Stephen V. Liu, Gregory P. Kalemkerian, Yariv Houvras, Daniel W. Bowles, Aaron S. Mansfield, W. Marston Linehan, Vlatka Smoljanović, Ahmadur Rahman, Shengchun Kong, Alena Zalutskaya, Melinda Louie-Gao, Andy Boral, Julien Mazières - Annals of Oncology 2022 cited by 178

  23. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

    Authors: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock - Annals of Oncology 2020 cited by 250

  24. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

    Authors: Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo, Alfredo Addeo - Nature Reviews Clinical Oncology 2021 cited by 198